SCM
Superstring Capital Management Portfolio holdings
AUM
$80.3M
This Quarter Return
+57.27%
1 Year Return
+68.23%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$112M
AUM Growth
+$112M
(+41%)
Cap. Flow
+$29.7M
Cap. Flow
% of AUM
26.58%
Top 10 Holdings %
Top 10 Hldgs %
77.69%
Holding
47
New
8
Increased
7
Reduced
9
Closed
20
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
$9.97M |
| 2 |
Zai Lab
ZLAB
|
$9.94M |
| 3 |
Oric Pharmaceuticals
ORIC
|
$9.73M |
| 4 |
Instil Bio
TIL
|
$7.24M |
| 5 |
Capricor Therapeutics
CAPR
|
$5.13M |
Top Sells
| 1 |
Legend Biotech
LEGN
|
$4.59M |
| 2 |
Keros Therapeutics
KROS
|
$3.39M |
| 3 |
Arcellx
ACLX
|
$3.26M |
| 4 |
Arrowhead Research
ARWR
|
$2.89M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$1.78M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zai Lab
ZLAB
$3.68B
| $15.1M | 13.25% | 626,932 +411,754 | +191% | +$9.94M |
|
2
Cytokinetics
CYTK
$4.23B
| $11.4M | 9.97% | 215,798 +28,165 | +15% | +$1.49M |
|
3
Terns Pharmaceuticals
TERN
$609M
| $11.2M | 9.84% | 1,348,546 +392,004 | +41% | +$3.27M |
|
|
4
Structure Therapeutics
GPCR
$1.11B
| $9.97M | 8.72% | +227,047 | New | +$9.97M |
|
|
5
Oric Pharmaceuticals
ORIC
$994M
| $9.73M | 8.52% | +949,522 | New | +$9.73M |
|
|
6
Instil Bio
TIL
$182M
| $7.24M | 6.34% | +107,545 | New | +$7.24M |
|
7
NovoCure
NVCR
$1.38B
| $6.14M | 5.37% | 392,711 +325,819 | +487% | +$5.09M |
|
8
BridgeBio Pharma
BBIO
$9.89B
| $5.77M | 5.05% | 226,684 +6,847 | +3% | +$174K |
|
9
Fate Therapeutics
FATE
$120M
| $5.13M | 4.49% | 1,466,934 +969,574 | +195% | +$3.39M |
|
|
10
Capricor Therapeutics
CAPR
$287M
| $5.13M | 4.49% | +337,347 | New | +$5.13M |
|
11
Tango Therapeutics
TNGX
$747M
| $4.61M | 4.04% | 599,048 +483,477 | +418% | +$3.72M |
|
12
89bio
ETNB
$1.34B
| $4.4M | 3.86% | 595,203 -85,200 | -13% | -$630K |
|
13
Nkarta
NKTX
$151M
| $3.35M | 2.93% | 740,294 -135,705 | -15% | -$613K |
|
|
14
Legend Biotech
LEGN
$6.41B
| $2.95M | 2.58% | 60,515 -94,150 | -61% | -$4.59M |
|
|
ZBIO
15
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $1.89M | 1.65% | +111,605 | New | +$1.89M |
|
16
Allogene Therapeutics
ALLO
$251M
| $1.34M | 1.17% | 478,115 -211,797 | -31% | -$593K |
|
17
Spyre Therapeutics
SYRE
$996M
| $1.1M | 0.96% | 37,287 -8,284 | -18% | -$244K |
|
18
Savara
SVRA
$567M
| $848K | 0.74% | 200,000 | – | – |
|
19
Biomea Fusion
BMEA
$116M
| $844K | 0.74% | 83,554 -83,556 | -50% | -$844K |
|
20
Tourmaline Bio
TRML
$601M
| $748K | 0.65% | 29,104 -66,125 | -69% | -$1.7M |
|
21
Zura Bio
ZURA
$133M
| $636K | 0.56% | 156,626 | – | – |
|
22
Cabaletta Bio
CABA
$133M
| $622K | 0.54% | 131,795 -8,100 | -6% | -$38.2K |
|
23
Corbus Pharmaceuticals
CRBP
$115M
| $524K | 0.46% | 25,401 -31,067 | -55% | -$641K |
|
24
Immunovant
IMVT
$2.56B
| $355K | 0.31% | +12,447 | New | +$355K |
|
25
Cullinan Oncology
CGEM
$445M
| $349K | 0.31% | +20,840 | New | +$349K |
|